CONMED Shares Decline Following Strategic Withdrawal from Gastroenterology Portfolio
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Should l Buy MEDP?
Source: NASDAQ.COM
CONMED's Strategic Shift: CONMED announced its exit from gastroenterology product lines, including an early termination of its distribution agreement with Gore for the VIABIL biliary stent, to focus on core areas like minimally invasive and orthopedic soft tissue surgery.
Financial Impact: The company expects a revenue loss of $90–$95 million from the gastroenterology segment in 2025 and anticipates earnings per share dilution of 45–55 cents in 2026, but aims to improve its gross margin profile by about 80 basis points in the long run.
Market Reaction: Following the announcement, CONMED's shares fell over 9%, reflecting investor concerns, as the company has seen a 41.5% decline in stock value year-to-date compared to industry growth.
Future Outlook: The exit is expected to streamline CONMED’s operations, enhance profitability, and allow for better resource allocation towards higher-growth potential areas, ultimately aiming for a more resilient business model.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 451.760
Low
462.00
Averages
569.17
High
660.00
Current: 451.760
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bragar Eagel & Squire Investigates Potential Claims Against Medpace
- Financial Performance Analysis: Medpace's Q4 2025 earnings report, released on February 9, 2026, revealed revenues of $708.5 million and GAAP EPS of $4.67, both exceeding market expectations; however, the book-to-bill ratio of 1.04 fell short of the company's forecasts, indicating potential risks to business growth.
- Impact of Cancellations: CEO August Troendle acknowledged that cancellations reached their highest level in over a year, particularly in the metabolic area, although no single large project was responsible, contrasting sharply with previous optimistic projections and potentially raising investor concerns about future performance.
- Stock Price Reaction: Following the earnings disclosure on February 10, 2026, Medpace's shares plummeted approximately 15.9%, with multiple financial outlets identifying the bookings miss as the primary driver of the sell-off, reflecting a significant loss of market confidence in the company's growth prospects.
- Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating whether Medpace has violated federal securities laws, encouraging affected investors to reach out to discuss their legal rights, indicating that the company may face potential legal risks that could impact its reputation and shareholder confidence.
See More
Tom Gardner Discusses AI and Investment Strategies
- Rise of AI Native Companies: Tom Gardner emphasizes that future winners will be AI native companies that fully integrate AI into their culture, enabling them to achieve higher productivity with fewer employees, thus gaining a competitive edge.
- Market Indicator Analysis: Gardner utilizes the Potential Growth Indicator and Market View Tool to guide investment decisions, with the former indicating potential market overvaluation and expected annual returns between 8.5% and 9%, while the latter forecasts closer to 10.5%, reflecting the market's complexity.
- Portfolio Strategy: Gardner stresses that investors should adopt an incremental strategy, focusing on cash inflows into the market to avoid significant losses during market volatility, particularly for those nearing retirement who need to manage their assets cautiously.
- Stock Recommendations for the Next Five Years: He recommends six stocks, including TransMedics, which is expected to triple in value over the next 6-7 years, and Aritzia, which shows strong financial management and growth potential in the U.S. market.
See More
Market Mechanics Influence Stock Price Swings
- Price Volatility Drivers: Market mechanics play a crucial role in the dramatic price swings of stocks, exemplified by Medpace, which saw a price increase of 2.86%.
- Investor Strategies: Investors must understand market dynamics and mechanics to effectively navigate these fluctuations, ensuring informed decision-making in uncertain market conditions.
- Video Learning Resource: The provided video content delves into various factors influencing stock prices, equipping investors with techniques to manage market volatility.
- Market Psychology Impact: Beyond news events, market psychology and investor sentiment significantly affect stock prices, and understanding these factors aids investors in better predicting market trends.
See More
Ten Large-Cap Stocks with Worst Performance Last Week
- Astera Labs: Astera Labs (NASDAQ:ALAB) saw a significant decline of 23.74% this week after reporting fourth-quarter financial results that fell short of market expectations, raising investor concerns about its future profitability.
- Medpace Holdings: Medpace Holdings (NASDAQ:MEDP) experienced a slump of 20.69% this week, driven by disappointing fourth-quarter results and multiple analyst firms lowering their price targets, which intensified negative sentiment around the stock.
- Zillow Group: Zillow Group (NASDAQ:Z) decreased by 20.89% this week due to mixed fourth-quarter financial results that failed to boost investor confidence, leading to downward pressure on its stock price.
- AST SpaceMobile: AST SpaceMobile (NASDAQ:ASTS) fell 17.9% this week after announcing a $1 billion convertible senior notes offering, which was met with negative market reactions due to concerns over the implications of its financing plans.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment regarding these firms' prospects, which could influence investor decisions and market dynamics.
- Upgrades and Downgrades: While specific names of upgrades and downgrades are not detailed, such changes typically have a direct impact on the short-term performance of the affected stocks, prompting investors to pay close attention to these shifts.
- Market Reaction Expectations: Adjustments in analyst ratings may trigger market volatility, especially when investor expectations are high for certain stocks, potentially leading to significant price fluctuations.
- Investor Decision Impact: Investors considering buying WMT stock should take into account the latest insights from analysts to make more informed investment decisions, even though specific analyst opinions were not elaborated in the report.
See More
U.S. Markets Closed Tuesday with Mixed Results as Spotify Technology Outperformed and Medpace Holdings Underperformed
- U.S. Stock Market Performance: Stock indexes in the U.S. closed mixed on Tuesday, with the S&P 500 increasing by 0.10%.
- Decline in Other Indexes: The Dow Jones Industrial Average declined by 0.33%, while the Nasdaq Composite fell by 0.59%.
See More
Bragar Eagel & Squire Investigates Potential Claims Against Medpace
- Financial Performance Analysis: Medpace's Q4 2025 earnings report, released on February 9, 2026, revealed revenues of $708.5 million and GAAP EPS of $4.67, both exceeding market expectations; however, the book-to-bill ratio of 1.04 fell short of the company's forecasts, indicating potential risks to business growth.
- Impact of Cancellations: CEO August Troendle acknowledged that cancellations reached their highest level in over a year, particularly in the metabolic area, although no single large project was responsible, contrasting sharply with previous optimistic projections and potentially raising investor concerns about future performance.
- Stock Price Reaction: Following the earnings disclosure on February 10, 2026, Medpace's shares plummeted approximately 15.9%, with multiple financial outlets identifying the bookings miss as the primary driver of the sell-off, reflecting a significant loss of market confidence in the company's growth prospects.
- Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating whether Medpace has violated federal securities laws, encouraging affected investors to reach out to discuss their legal rights, indicating that the company may face potential legal risks that could impact its reputation and shareholder confidence.
See More
Tom Gardner Discusses AI and Investment Strategies
- Rise of AI Native Companies: Tom Gardner emphasizes that future winners will be AI native companies that fully integrate AI into their culture, enabling them to achieve higher productivity with fewer employees, thus gaining a competitive edge.
- Market Indicator Analysis: Gardner utilizes the Potential Growth Indicator and Market View Tool to guide investment decisions, with the former indicating potential market overvaluation and expected annual returns between 8.5% and 9%, while the latter forecasts closer to 10.5%, reflecting the market's complexity.
- Portfolio Strategy: Gardner stresses that investors should adopt an incremental strategy, focusing on cash inflows into the market to avoid significant losses during market volatility, particularly for those nearing retirement who need to manage their assets cautiously.
- Stock Recommendations for the Next Five Years: He recommends six stocks, including TransMedics, which is expected to triple in value over the next 6-7 years, and Aritzia, which shows strong financial management and growth potential in the U.S. market.
See More
Market Mechanics Influence Stock Price Swings
- Price Volatility Drivers: Market mechanics play a crucial role in the dramatic price swings of stocks, exemplified by Medpace, which saw a price increase of 2.86%.
- Investor Strategies: Investors must understand market dynamics and mechanics to effectively navigate these fluctuations, ensuring informed decision-making in uncertain market conditions.
- Video Learning Resource: The provided video content delves into various factors influencing stock prices, equipping investors with techniques to manage market volatility.
- Market Psychology Impact: Beyond news events, market psychology and investor sentiment significantly affect stock prices, and understanding these factors aids investors in better predicting market trends.
See More
Ten Large-Cap Stocks with Worst Performance Last Week
- Astera Labs: Astera Labs (NASDAQ:ALAB) saw a significant decline of 23.74% this week after reporting fourth-quarter financial results that fell short of market expectations, raising investor concerns about its future profitability.
- Medpace Holdings: Medpace Holdings (NASDAQ:MEDP) experienced a slump of 20.69% this week, driven by disappointing fourth-quarter results and multiple analyst firms lowering their price targets, which intensified negative sentiment around the stock.
- Zillow Group: Zillow Group (NASDAQ:Z) decreased by 20.89% this week due to mixed fourth-quarter financial results that failed to boost investor confidence, leading to downward pressure on its stock price.
- AST SpaceMobile: AST SpaceMobile (NASDAQ:ASTS) fell 17.9% this week after announcing a $1 billion convertible senior notes offering, which was met with negative market reactions due to concerns over the implications of its financing plans.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment regarding these firms' prospects, which could influence investor decisions and market dynamics.
- Upgrades and Downgrades: While specific names of upgrades and downgrades are not detailed, such changes typically have a direct impact on the short-term performance of the affected stocks, prompting investors to pay close attention to these shifts.
- Market Reaction Expectations: Adjustments in analyst ratings may trigger market volatility, especially when investor expectations are high for certain stocks, potentially leading to significant price fluctuations.
- Investor Decision Impact: Investors considering buying WMT stock should take into account the latest insights from analysts to make more informed investment decisions, even though specific analyst opinions were not elaborated in the report.
See More
U.S. Markets Closed Tuesday with Mixed Results as Spotify Technology Outperformed and Medpace Holdings Underperformed
- U.S. Stock Market Performance: Stock indexes in the U.S. closed mixed on Tuesday, with the S&P 500 increasing by 0.10%.
- Decline in Other Indexes: The Dow Jones Industrial Average declined by 0.33%, while the Nasdaq Composite fell by 0.59%.
See More
